Baird Maintains Outperform on Twist Bioscience, Raises Price Target to $46
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Catherine Ramsey maintains an Outperform rating on Twist Bioscience (NASDAQ:TWST) and raises the price target from $40 to $46.
August 05, 2024 | 11:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst Catherine Ramsey maintains an Outperform rating on Twist Bioscience and raises the price target from $40 to $46.
The raised price target and maintained Outperform rating from a reputable analyst are likely to positively impact investor sentiment and drive short-term price appreciation for Twist Bioscience.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100